Renaissance Technologies
CYCN icon

Renaissance Technologies’s Cyclerion Therapeutics CYCN Stock Holding History

Renaissance Technologies’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,611
Closed -$34.2K – 3526
2024
Q4 		$34.2K Buy
+10,611
New +$29.5K ﹤0.01% 3432
2023
Q2 		– Sell
-4,335
Closed -$38K – 3984
2023
Q1 		$38K Sell
4,335
-4,844
-53% -$61.1K ﹤0.01% 3713
2022
Q4 		$120K Sell
9,179
-4,990
-35% -$59K ﹤0.01% 3562
2022
Q3 		$244K Sell
14,169
-8,635
-38% -$148K ﹤0.01% 3296
2022
Q2 		$250K Buy
22,804
+7,676
+51% +$110K ﹤0.01% 3550
2022
Q1 		$336K Sell
15,128
-2,167
-13% -$52.2K ﹤0.01% 3417
2021
Q4 		$595K Buy
17,295
+13,680
+378% +$646K ﹤0.01% 2993
2021
Q3 		$222K Sell
3,615
-10,622
-75% -$695K ﹤0.01% 3170
2021
Q2 		$1.11M Buy
14,237
+2,577
+22% +$161K ﹤0.01% 2622
2021
Q1 		$651K Buy
11,660
+10,765
+1,203% +$809K ﹤0.01% 2804
2020
Q4 		$55K Buy
+895
New +$61K ﹤0.01% 3312
2020
Q3 		– Sell
-4,250
Closed -$502K – 3423
2020
Q2 		$502K Buy
4,250
+1,460
+52% +$122K ﹤0.01% 2874
2020
Q1 		$148K Buy
+2,790
New +$199K ﹤0.01% 3160

Other funds holding CYCN

TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Renaissance Technologies's CYCN Position: Q1 2025 in Review

Renaissance Technologies sold out of Cyclerion Therapeutics (CYCN) in Q1 2025, closing a stake of 10,611 shares — an estimated $34.2K sold.

Renaissance Technologies first reported a position in CYCN in Q1 2020 and held it in 13 quarters. The position peaked at $1.11M in Q2 2021. 18 funds tracked by Wall St. Rank hold CYCN as of Q1 2025.

  • Renaissance Technologies reported no remaining Cyclerion Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Renaissance Technologies sold 10,611 Cyclerion Therapeutics shares in Q1 2025, an estimated $34.2K.
  • Renaissance Technologies first reported a position in Cyclerion Therapeutics in Q1 2020 and held it in 13 quarters.
  • Renaissance Technologies's Cyclerion Therapeutics position peaked at $1.11M in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2025.

Based on Renaissance Technologies's 13F filing for Q1 2025, filed 14 May 2025.